Tag Archives: Swift Biosciences

July 2017—Swift Biosciences has commercially released its Accel-Amplicon CFTR Panel, which aims to provide research laboratories with a more comprehensive, next-generation sequencing–based approach to interrogate the coding region and select introns within the cystic fibrosis transmembrane conductance regulator gene for disease-relevant mutations and variants. The panel is designed to offer a higher resolution view into the CFTR gene and produces ready-to-sequence libraries in two hours.

April 2016—Swift Biosciences and SeraCare Life Sciences will partner to accelerate development of a novel circulating tumor DNA reference material.

January 2016—Swift Biosciences will incorporate Horizon Discovery Group’s human genomic reference standards into its new Accel-Amplicon 56G Oncology Panel for use in research and translational applications.

Fluxion Biosciences and Swift Biosciences announced a jointly developed workflow for oncology clinical research designed to detect somatic mutations from a routine blood draw. The workflow uses Fluxion’s IsoFlux System for circulating tumor cell enrichment and Swift’s Accel-Amplicon technology for high-sensitivity variant detection using low starting inputs.

February 2014—Swift Biosciences announced the launch of the Accel-NGS PCR-free DNA Library Kit for Illumina next-generation sequencing systems. The kit is designed to bring low input requirement, PCR-free capability, and fast, easy workflow to the Illumina platform.